{"protocolSection": {"identificationModule": {"nctId": "NCT02004886", "orgStudyIdInfo": {"id": "0893-005"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)", "officialTitle": "A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-08-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2007-02-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-02-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-12-03", "studyFirstSubmitQcDate": "2013-12-03", "studyFirstPostDateStruct": {"date": "2013-12-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-01-31", "resultsFirstSubmitQcDate": "2014-01-31", "resultsFirstPostDateStruct": {"date": "2014-03-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-07", "lastUpdatePostDateStruct": {"date": "2018-09-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus. The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Therapeutic Uses", "Pharmacologic Actions", "Molecular Mechanisms of Pharmacological Action", "Physiological Effects of Drugs", "Metformin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 74, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-0893 (40 mg)", "type": "EXPERIMENTAL", "description": "MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.", "interventionNames": ["Drug: MK-0893", "Drug: Placebo"]}, {"label": "MK-0893 (120 mg)", "type": "EXPERIMENTAL", "description": "MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893", "interventionNames": ["Drug: MK-0893", "Drug: Placebo"]}, {"label": "Metformin (2000 mg)", "type": "ACTIVE_COMPARATOR", "description": "Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.", "interventionNames": ["Drug: Metformin", "Drug: Placebo"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo tablets matching the MK-0893 and placebo tablets matching metformin.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "MK-0893", "description": "10 mg and 100 mg tablets", "armGroupLabels": ["MK-0893 (120 mg)", "MK-0893 (40 mg)"]}, {"type": "DRUG", "name": "Metformin", "description": "500 mg metformin tablets", "armGroupLabels": ["Metformin (2000 mg)"], "otherNames": ["Glucophage", "Glucophage XR", "Glumetza", "Fortamet", "Riomet"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo tablets matching MK-0893", "armGroupLabels": ["MK-0893 (120 mg)", "MK-0893 (40 mg)", "Metformin (2000 mg)", "Placebo"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo tablets matching metformin", "armGroupLabels": ["MK-0893 (120 mg)", "MK-0893 (40 mg)", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4", "description": "Blood samples were collected 30 minutes prior to all meals, and 15, 30, 60, 90, 120, 180 minutes post-meal, then and at midnight, 3 AM, and the next morning at 6:30 AM and 7:30 AM. A 24-hour weighted mean glucose (WMG) was determined by averaging multiple plasma glucose measurements over a 24-hour period.", "timeFrame": "Baseline and Week 4"}, {"measure": "Number of Participants Experiencing an Adverse Event (AE)", "description": "An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "timeFrame": "Up to 42 days"}, {"measure": "Number of Participants Discontinuing Study Treatment Due to an AE", "description": "An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "timeFrame": "Up to 28 days"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Plasma Glucose levels were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Fructosamine at Week 4", "description": "Fructosamine levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Fasting C-peptide at Week 4", "description": "Fasting C-peptide levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Fasting Insulin at Week 4", "description": "Fasting insulin levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in 2-hour Post-prandial Glucose Excursion at Week 4", "description": "2-hour post-prandial glucose excursion is the change in glucose concentration in the blood 2 hours after a meal. Change from baseline in 2-hour post-prandial glucose excursion at Week 4 is defined as Week 4 minus baseline.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in 3-hour Area Under the Plasma Concentration Versus Time Curve (AUC) for Glucose at Week 4", "description": "Blood samples collected for glucose 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for Glucose was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in 3-hour AUC for C-peptide at Week 4", "description": "Blood samples were collected for C-peptide 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for C-peptide was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in 3-hour Insulin Total AUC at Week 4", "description": "Blood samples were collected for insulin 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour Insulin Total AUC was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "timeFrame": "Baseline and Week 4"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones \\[i.e., peroxisome proliferator activated receptor-gamma, PPAR\u03b3 agents\\])\n* male or a female of non-childbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized\n* A body mass index (BMI) that is \\> 20 and \u2264 40 kg/m2\n\nExclusion Criteria:\n\n* History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes\n* History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy\n* Treatment for diabetes within 3 months of study participation with combination anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone)\n* oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarin-like anticoagulants, theophylline, anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic agents, or herbal remedies\n* History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)\n* History of gastrointestinal problems or disorders or extensive bowel or gastric surgery\n* History of significant or unstable cardiovascular disease\n* History of neoplastic disease\n* History of hepatic disease\n* History of seizures, epilepsy or other neurologic disease\n* History of myelodysplastic or pre-leukemic disorders or other severe hematological disorder", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "referencesModule": {"availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=0893-005&kw=0893-005&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 13 clinical sites were used in this study in the following countries: Austria, Germany, New Zealand, Russia, and the United States of America.", "groups": [{"id": "FG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "FG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "FG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "FG003", "title": "Placebo", "description": "Placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Unable to attend future visits", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "BG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "BG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "BG003", "title": "Placebo", "description": "Placebo"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "19"}, {"groupId": "BG004", "value": "74"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.5", "spread": "7.1"}, {"groupId": "BG001", "value": "55.8", "spread": "6.8"}, {"groupId": "BG002", "value": "54.7", "spread": "8.7"}, {"groupId": "BG003", "value": "51.5", "spread": "9.3"}, {"groupId": "BG004", "value": "54.1", "spread": "8.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "36"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "12"}, {"groupId": "BG004", "value": "38"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4", "description": "Blood samples were collected 30 minutes prior to all meals, and 15, 30, 60, 90, 120, 180 minutes post-meal, then and at midnight, 3 AM, and the next morning at 6:30 AM and 7:30 AM. A 24-hour weighted mean glucose (WMG) was determined by averaging multiple plasma glucose measurements over a 24-hour period.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.9", "lowerLimit": "-47.1", "upperLimit": "-28.8"}, {"groupId": "OG001", "value": "-65.7", "lowerLimit": "-74.8", "upperLimit": "-56.5"}, {"groupId": "OG002", "value": "-38.1", "lowerLimit": "-47.0", "upperLimit": "-29.2"}, {"groupId": "OG003", "value": "-12.0", "lowerLimit": "-20.7", "upperLimit": "-3.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Terms for treatment, prior AHA therapy status, and baseline 24-hour WMG value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-25.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.4", "ciUpperLimit": "-13.3"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Terms for treatment, prior AHA therapy status, and baseline 24-hour WMG value as a covariate.", "paramType": "Median Difference (Final Values)", "paramValue": "-53.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-66.1", "ciUpperLimit": "-41.1"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Terms for treatment, prior AHA therapy status, and baseline 24-hour WMG value as a covariate.", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.4", "ciUpperLimit": "-13.6"}]}, {"type": "PRIMARY", "title": "Number of Participants Experiencing an Adverse Event (AE)", "description": "An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "populationDescription": "Safety Population included all randomized participants who initiated study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Participants", "timeFrame": "Up to 42 days", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "8"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Discontinuing Study Treatment Due to an AE", "description": "An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "populationDescription": "Safety Population included all randomized participants who initiated study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of Participants", "timeFrame": "Up to 28 days", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG)", "description": "Plasma Glucose levels were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-32.5", "lowerLimit": "-45.1", "upperLimit": "-19.8"}, {"groupId": "OG001", "value": "-57.7", "lowerLimit": "-70.3", "upperLimit": "-45.1"}, {"groupId": "OG002", "value": "-22.8", "lowerLimit": "-35.0", "upperLimit": "-10.5"}, {"groupId": "OG003", "value": "-14.1", "lowerLimit": "-26.1", "upperLimit": "-2.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.04", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.7", "ciUpperLimit": "-0.9"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-43.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-60.9", "ciUpperLimit": "-26.3"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.320", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-8.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.7", "ciUpperLimit": "8.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fructosamine at Week 4", "description": "Fructosamine levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting C-peptide at Week 4", "description": "Fasting C-peptide levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.4", "lowerLimit": "-0.5", "upperLimit": "0.7"}, {"groupId": "OG001", "value": "-0.3", "spread": "0.3", "lowerLimit": "-0.8", "upperLimit": "0.3"}, {"groupId": "OG002", "value": "-0.1", "spread": "0.3", "lowerLimit": "-0.6", "upperLimit": "0.5"}, {"groupId": "OG003", "value": "-0.0", "spread": "0.2", "lowerLimit": "-0.6", "upperLimit": "0.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.751", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.7", "ciUpperLimit": "0.9"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.581", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.0", "ciUpperLimit": "0.6"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.918", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.8", "ciUpperLimit": "0.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Insulin at Week 4", "description": "Fasting insulin levels in the blood were measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "\u03bcIU/mL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}, {"groupId": "OG003", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "Data for this outcome measure were not collected or analyzed."}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post-prandial Glucose Excursion at Week 4", "description": "2-hour post-prandial glucose excursion is the change in glucose concentration in the blood 2 hours after a meal. Change from baseline in 2-hour post-prandial glucose excursion at Week 4 is defined as Week 4 minus baseline.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.5", "lowerLimit": "-20.2", "upperLimit": "-0.8"}, {"groupId": "OG001", "value": "-15.3", "lowerLimit": "-25.1", "upperLimit": "-5.5"}, {"groupId": "OG002", "value": "-29.0", "lowerLimit": "-38.4", "upperLimit": "-19.5"}, {"groupId": "OG003", "value": "-2.8", "lowerLimit": "-12.2", "upperLimit": "6.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.253", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-7.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.1", "ciUpperLimit": "5.6"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.070", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-12.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.0", "ciUpperLimit": "1.0"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.5", "ciUpperLimit": "-12.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 3-hour Area Under the Plasma Concentration Versus Time Curve (AUC) for Glucose at Week 4", "description": "Blood samples collected for glucose 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for Glucose was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg hr/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-128.8", "lowerLimit": "-169.5", "upperLimit": "-88.2"}, {"groupId": "OG001", "value": "-230.2", "lowerLimit": "-270.5", "upperLimit": "-189.9"}, {"groupId": "OG002", "value": "-136.7", "lowerLimit": "-175.7", "upperLimit": "-97.6"}, {"groupId": "OG003", "value": "-39.0", "lowerLimit": "-77.3", "upperLimit": "-0.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-89.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-145.6", "ciUpperLimit": "-34.0"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-191.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-246.4", "ciUpperLimit": "-135.9"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Relevant baseline efficacy measurements were the covariates.", "paramType": "Mean Difference (Final Values)", "paramValue": "-97.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-152.4", "ciUpperLimit": "-42.9"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 3-hour AUC for C-peptide at Week 4", "description": "Blood samples were collected for C-peptide 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour AUC for C-peptide was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng hr/mL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "lowerLimit": "-0.9", "upperLimit": "2.9"}, {"groupId": "OG001", "value": "-0.5", "lowerLimit": "-2.5", "upperLimit": "1.4"}, {"groupId": "OG002", "value": "-0.2", "lowerLimit": "-2.1", "upperLimit": "1.6"}, {"groupId": "OG003", "value": "-0.1", "lowerLimit": "-1.9", "upperLimit": "1.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.408", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.5", "ciUpperLimit": "3.7"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.741", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.1", "ciUpperLimit": "2.2"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.906", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.8", "ciUpperLimit": "2.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 3-hour Insulin Total AUC at Week 4", "description": "Blood samples were collected for insulin 30 minutes prior to the breakfast meal and 15, 30, 60, 90, 120, 180 minutes post-meal. AUC is a measure of the amount of drug in the blood over time. 3-hour Insulin Total AUC was measured at Baseline and at Week 4. The change from baseline was defined as the Week 4 value minus the Baseline value.", "populationDescription": "Completers Population was used for all efficacy analyses, and required that a participant took at least one dose of study therapy, had a baseline measurement, and had a post-randomization measurement in the treatment period at Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "\u00b5IU hr/mL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily"}, {"id": "OG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily"}, {"id": "OG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily"}, {"id": "OG003", "title": "Placebo", "description": "Placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.3", "lowerLimit": "-15.5", "upperLimit": "26.1"}, {"groupId": "OG001", "value": "6.1", "lowerLimit": "-15.3", "upperLimit": "27.6"}, {"groupId": "OG002", "value": "1.2", "lowerLimit": "-18.4", "upperLimit": "20.7"}, {"groupId": "OG003", "value": "7.8", "lowerLimit": "-11.2", "upperLimit": "26.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.857", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.4", "ciUpperLimit": "25.3"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.906", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.3", "ciUpperLimit": "26.9"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.630", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.0", "ciUpperLimit": "20.8"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 42 days", "description": "Safety Population included all randomized participants who initiated study therapy. Adverse events were collected up to 14 days after last dose of study drug.", "eventGroups": [{"id": "EG000", "title": "MK-0893 (40 mg)", "description": "MK-0893 40-mg, once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 3, "otherNumAtRisk": 19}, {"id": "EG001", "title": "MK-0893 (120 mg)", "description": "MK-0893, 120 mg, once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 7, "otherNumAtRisk": 18}, {"id": "EG002", "title": "Metformin (2000 mg)", "description": "Metformin, oral, 1000 mg, twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 9, "otherNumAtRisk": 18}, {"id": "EG003", "title": "Placebo", "description": "Placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 8, "otherNumAtRisk": 19}], "otherEvents": [{"term": "External Ear Pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Eye Irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Vision Blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Abdominal Pain Lower", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Dry Mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Gingival Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Stomach Discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Chest Discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Feeling Abnormal", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Nodule", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Thirst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Herpes Simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Otitis Media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Viral Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Fluid Retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Testicular Pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Pharyngolaryngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Rales", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Rash Erythematous", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 9.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 19}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 19}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}